Category: Roivant

Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance

Alliance will include Roivant’s ownership interests in Myovant, Urovant, Enzyvant, Altavant, and Spirovant, a new company focused on developing innovative gene therapies for cystic fibrosis Sumitomo Dainippon Pharma will leverage Roivant’s technology platforms to digitally transform its business The new company will be led by Chief Executive Officer Myrtle Potter, former President and COO of…

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients

Sumitomo Dainippon-Roivant Alliance (“Alliance”) encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation Sumitomo Dainippon Pharma to enter into contract agreements with Roivant Health technology Vants including…

Roivant Provides Corporate Updates in Advance of Second Annual Pipeline Day

Webcast of Pipeline Day presentations will be available here NEW YORK and BASEL, Switzerland, June 5, 2019 /PRNewswire/ — Roivant Sciences today announced a series of corporate updates across the Roivant family of companies in advance of its second annual Pipeline Day tomorrow afternoon in New York City. Immunovant announced the appointment of Dr. Pete…

Roivant Statement on Positive Phase 3 Results from Myovant’s LIBERTY 1 Study in Uterine Fibroids

Second annual Roivant Pipeline Day on June 6th to feature additional clinical data from across Roivant family of companies NEW YORK and BASEL, Switzerland, May 14, 2019 /PRNewswire/ — Roivant subsidiary Myovant Sciences today announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids. An estimated 5…

Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder

Vibegron met both co-primary endpoints and all seven key secondary endpoints Seven additional Phase 3 readouts expected over the next 18 months across the Roivant family of companies Second annual Roivant Pipeline Day to be held on June 6th in New York City NEW YORK and BASEL, Switzerland, March 19, 2019 /PRNewswire/ — Today Roivant subsidiary…

Roivant Announces Corporate Updates and Webcast of Presentation at 37th Annual J.P. Morgan Healthcare Conference

Roivant launches Alyvant, a new Vant focused on tech-enabled pharma commercialization, and unveils agreement for co-promotion of three approved medicines Urovant, Axovant, Dermavant, and Altavant announce additional corporate updates; preliminary clinical data for anti-FcRn antibody RVT-1401 to be presented Monday at JPM conference Key events across Roivant family in 2019 include potential FDA decision on…